Joseph Schwartz
Analyst, SVB Lyric
Replay available
Gossamer Bio (NASDAQ:GOSS) Q3 2019 earnings call, held 2019-11-12. Watch the replay and read the transcript on 6ix.

On 6ix: 6ix.com/event/gossamer-bio-inc-goss-q3-2019-earnings-call
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:01 Good afternoon, and welcome to the Gossamer Bio third quarter 2019 earnings call. Today's call will feature updates from Gossamer Bio's management team, followed by a question and answer session. I will now turn the call over to Gossamer Bio's Chief Financial Officer, Bryan Giraudo. Bryan?
0:20 Thank you, Operator, and thank you all for joining us this afternoon. I'm joined on today's call by Gossamer Bio's Co-Founder and Chief Executive Officer, Dr. Sheila Giraudo. As well as Gossamer's Chief Medical Officer, Dr. Jacob DuPont, and Gossamer's Chief Scientific Officer, Dr. Louisa Salter-Sitt. Earlier this afternoon, Gossamer Bio issued a press release announcing its financial results for the third quarter ended September 30, 2019, and provided a corporate update. Please note that certain information discussed on the call today is covered under the safe harbor provision of the Private Securities Litigation Reform Act. We caution listeners that during this call, Gossamer management will be making Forward-looking statements. Actual results may differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business.
1:10 These forward-looking statements are qualified by the statements contained in Gossamer's news releases and SEC filings, including in the annual report on Form 10-K and subsequent filings. This conference call also contains time-sensitive information that may be accurate for only a limited period of time. Gossamer Bio undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call. Now I'd like to turn the call over to Sheila. Sheila?
1:39 Thank you, Bryan, and good afternoon to everyone joining us on today's call. Since our initial public offering in February of this year, I have emphasized that Gossamer Bio's goal is to be an industry leader in immunology, inflammation, and oncology, and to enhance and extend the lives of patients suffering from such diseases. On today's call, I am excited to further update you on Gossamer's continued progress towards that ambitious goal. I will walk you through the updates and milestones achieved for each of our four clinical stage product candidates, and then Bryan will discuss Gossamer's financial updates, following which I will provide a few closing remarks. We will begin with our most advanced clinical stage product candidate, GB001, an oral DP2 antagonist, which we are developing for eosinophilic asthma and other allergic conditions, including chronic rhinositis, both with and without nasal polyps, and chronic spontaneous urticaria.
2:34 Gossamer Bio continues to enroll the LIDA study for the treatment of moderate to severe eosinophilic asthma. LIDA is a global Phase IIb study testing GB001 over a 24-week treatment period with patients remaining on background therapy. As a reminder, the LIDA study is enrolling a gene of step 4 and 5 patient population, all of whom must have an easiness of count of at least 250 cells per microliter. LIDA uses reduction in asthma worsening, a composite measure, at 24 weeks as its primary endpoint. The study is on track to trigger an interim analysis in the first half of 2020, once approximately two-thirds of the patients have completed the trial. In the second half of 2020, we expect to read out full top-line phase 2B results for this 400-patient trial.
3:23 In September, at the European Respiratory Society International Congress in Madrid, we presented a poster further detailing GB001's effects in relation to fractional-scale nitrous oxide, or PHENO, in mild to moderate atopic asthmatics. The data described in the poster suggests that phenol could serve as a useful prognostic marker for treatment response to GB001, in addition to elevated eosinophils, which is the marker we are currently using to enroll the lead of study. The high phenol subpopulation for patients with phenol greater than or equal to 35 parts per billion showed a phenol reduction versus placebo of 13.4 parts per billion. The high pheno subpopulation also showed a mean FEV1 improvement at Phase 28 versus placebo of 207 mL.
4:13 In our ongoing Phase II LIDA study, we continue to evaluate pheno as a potential biomarker. Late this past week, at the American College of Allergy, Asthma, and Immunology Annual Scientific Meeting in Houston, we presented two posters related to asthma and GB001. The first contained detailed results from the previously discussed proof-of-concept Phase II study run by our partner, Cajun Pharma, and 158 Molotov Moderate Japanese mathematics. The study met its primary endpoint of change in morning peak expiratory flow from baseline versus placebo. Additionally, in the poster, we showed that treatment with 20 milligrams of GB001 led to a 71% reduction in the risk of asthma worsening in the overall population and an 84% reduction in the elevated eosinophil population.
5:04 These data reinforce our belief that baseline blood eosinophils are a potential useful marker for response to GB001. As part of our ongoing commercial characterization of the asthma market, the second poster from ACAAI details a real-world analysis of the dynamics and prescription trends for biologic usage in asthma. All three of these posters related to GD001 are available on our website at gosmerbio.com in the posters and publications section. On our previously quarterly call, we announced the first patient dose for our Phase II proof-of-concept study of GV001 in chronic rhinocytosis, known as the TITAN study. We plan to enroll approximately 100 patients with chronic rhinocytosis, both with and without nasal polyps, in the TITAN study, which is designed to measure the effect of GV001 on the sinonasal outcome test, or SNOT22 score.
6:00 After 16 weeks of treatment in patients who are refractory to intranasal steroids. We remain on track to read out top-line data for this proof-of-concept phase 2 study in the second half of 2020. Moving on to our third plan indication for GB001, chronic spontaneous urticaria, or CSU, there is evidence that the TH2 pathway and cell types, such as eosinophils, basophils, and mast cells, are implicated in the pathogenesis of CSU. But the underlying biology does differ from eosinophilic asthma and CRF. To better understand the effect of this difference in biology, combined with our desire to ensure we are targeting the right patient population, we have decided to initiate a smaller translational Phase II trial at CSU in the first half of 2020 prior to initiating a larger study.
6:50 We also continue to evaluate the potential of GV001 and other allergic and inflammatory diseases such as eosinophilic esophagitis. To close on GB001, we are very optimistic about the significant potential that this once-daily oral GP2 antagonist holds across multiple allergic disease areas with high unmet needs, and we look forward to reporting multiple Phase II top-line readouts in 2020. We'll now move on to GB002, our inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension, also known as PAH. GP002 has the potential to be the first drug in a new therapeutic class for this destructive and crippling rare disease with high unmet needs and limited classes of approved therapies.
7:36 GP002 has completed Phase I safety studies in normal healthy volunteers with no serious adverse events observed and has been granted orphan drug designation from the FDA and the EMA for the treatment of PAH. We've commenced an exploratory translational Phase 1b with the goals of assessing the initial safety and tolerability profile of GP02 in pH patients and generating target engagement and biomarker data. While we originally expected to begin patient enrollment in the third quarter of 2019, following the receipt of long-term toxicology data, we amended the trial protocol to include a six-month open-label extension following the original two-week study period. We've been working closely with our Phase 1B study sites and investigators to identify appropriate study participants for our Phase 1B study.
8:25 We expect to begin enrollment in the fourth quarter of 2019, and we expect an initial readout from the Phase 1B trial in the first half of 2020. As a reminder, this coming Sunday and Monday at the American Heart Association Scientific Sessions in Philadelphia, We are excited to present further GB002 preclinical data and two distinct animal models of PEH. The first presentation demonstrates that inhaled delivery of GB002 is efficacious in preventing pH progression in the RAP monocrytalline anemonectomy model in PEH, and furthermore that GB002 may be disease-modifying through its effect on lung remodeling in this rodent model. The second presentation details the results from GB002 in the SU50416 Hypoxia Rat Model, PAH. In this model, two weeks of treatment with GB002 significantly reduced right ventricular systolic pressure and mean pulmonary arterial pressure.
9:24 Additionally, decreased plasma levels of NT-proBNP, a biomarker for heart failure, were observed. Review the data presented in these presentations as very promising for the future of the GB00 program in PAH. and if you are our asset, AHA Sessions in Philadelphia, we welcome you to stop by. The abstracts of both presentations are currently on our website and both posters will become available on our website after the presentation. Additionally, based upon consultation with the regulatory authorities and KOLs, we are in the final stages of designing our GB002 Phase 2 study. While the Phase II study may not support registration, we believe that the data generated from this study will be incredibly valuable for future registrational studies by assessing PDR, cardiac function measured by echo, and six-minute walk tests.
10:15 We plan to initiate the Phase II study in the first half of next year. Next, we will discuss GB004, an oral hip one alpha stabilizer for the treatment of inflammatory bowel disease, including ulcerative colitis, or UC. GP004 is a gut-targeted, cobalt hydroxides inhibitor designed to preferentially stabilize HIF-1-alpha, a transcription factor involved in the body's protective response at low oxygen levels. We were very excited to see that in October it was announced that HIF Biology was subject of the work underlying the 2019 Nobel Prize in Medicine and Physiology. GP004 is currently in a Phase 1b designed to demonstrate proof of mechanism in UC patients. We are enrolling patients with active multi-moderate UC in this four-week study, which is testing one dose of GV004 versus placebo.
11:05 Patients enrolling in the trial must have active UC as confirmed by MEA4 assessment and evidence of colonic inflammation as confirmed by endoscopy. The primary outcome is safety and tolerability, and we plan to evaluate PKPD and hope to see evidence of target engagement, changes in gene expression, and epithelial barrier restoration. We are also collecting information on clinical effects in the study, including Mayo score, and after the treatment period, patients will undergo either flexible sigmoidoscopy or colonoscopy. We are pleased to say that we are on track to report initial top-line results from the Phase 1b in the first half of 2020. Finally, we will touch on our newest clinical asset, G1275, which is an oral CD11b modulator being developed as an immuno-oncology product candidate.
11:53 GP1275 is focused on addressing the immunosuppressive myeloid cell populations present within tumor tissues. These tumor types include pancreatic, colorectal, prostate, and other significant tumor indications. And GP1275 has received orphan drug designation from the FDA for the treatment of pancreatic cancer. This morning, we announced that we entered into a clinical trial collaboration and supply agreement with Merck. The study, now known as Keynote A36, is actively enrolling patients with pancreatic, gastric, colorectal, esophageal, and triple negative breast cancer. The baseline portion of the study consists of dose escalation of GP1275 monotherapy, and after clearing several monotherapy dose levels, we will initiate dose escalation combinations with Katrina or chemotherapy.
12:51 We are very excited to collaborate with Merck, an established leader in cancer immunotherapy, as we work to improve the lives of cancer patients. Our team presented a poster detailing the study design at last week's Society for Immunotherapy and Cancer meeting, which can now also be found on our website. We expect to disclose initial data from the study in the second half of 2020, and we will provide updates as the study progresses. Gossamer Bio retains worldwide rights to GP-1275. With that, I will hand it over to Gossamer Bio's Chief Financial Officer, Bryan Giraudo, for a financial update. Bryan?
13:26 Thank you, Sheila. We will now review the financial results for the second quarter of 2019. I'm sorry, the third quarter of 2019. We ended the quarter with $446 million of cash and cash equivalents. We continue to anticipate our cash and cash equivalents plus the capital available to us under our debt facility will provide us sufficient capital resources into the fourth quarter of 2021. Research and development expenses in the quarter were approximately $40.1 million, which reflects a continued ramp-up of expenses for GB001,002,004, and 1275. G&A expenses were $9.8 million in the quarter, with $3 million of that in total stock-based compensation. Our net loss for the quarter was $48.5 million, equating to $0.80 per share.
14:13 With that, I'll turn it back over to Sheila to offer some closing comments before we open the line for Q&A. Sheila?
14:19 Thank you, Bryan. As we draw the call to a close, we at Gossamer Bio would like to thank all our employees, shareholders, clinical trial participants, and investigators who have invested their time and resources for the betterment of patients. While we continually strive to advance our product candidates through the clinic, we know that our successes in the areas of immunology, inflammation, and oncology are not possible without your faith and commitment in our shared journey. Thank you for taking the time to join us today, and thank you for your continued interest and support. With that, I will now turn the call over to the operator to begin the question and answer session.
14:56 Operator? Ladies and gentlemen, if you have a question or comment at this time, please press star then 1 on your telephone keypad. If your question has been answered or you wish to remove yourself from the key, simply press the pound key. Again, if you have a question or comment at this time, please press star then 1 on your telephone keypad. Please stand by while we compile the Q&A roster. We have a question or comment from the line of Joseph Schwartz from SVB Lyric. Your line is open.
15:30 Great. Thanks very much. My only comment is congrats on the progress. And then for my first question, I was wondering on GB001, What is the baseline rate of asthma worsening that you expect to see in the patients you've enrolled in the LIDA study? What degree of improvement do you hope to show in this trial? And what kinds of events do you think GB001 has the best opportunity to reduce the rate of based on your understanding of the biology as well as the endpoint?
16:03 Great. Thank you, Joseph. So just to remind everyone, we are looking to enroll a and many more. So, in that respect, the patients we're going after typically will have an average of two exacerbations in the preceding year prior to the start of enrolling the study at baseline. So, in terms of what we would like to see for an improvement in that area, again, we're looking at asthma worsening, which is a broader composite endpoint Thank you. Thank you. and really everyone, too, when we think about the primary endpoint for looking at the LITA trial and looking at the primary endpoint for that study.
17:10 And then, of course, we will take that data to look at the Phase III endpoints, and we will be looking at exacerbations, which is an individual component of the five composite endpoint score that we'll be looking at, and we'll be using that to guide our Phase III planning and also to guide the exacerbation rate reduction we're hoping to see in the Phase III trial. And, of course, this is all predicated in that we are looking at the high EFAS population, and that's, again, been consistent with what we've been saying in terms of our ideal patient population from the beginning.
17:43 Okay, great. That's helpful. Thanks. And then on GB002, I was hoping that you can provide us some more color on your current plans for this program. I recall that the Phase 1B has two cohorts. and you were previously thinking that you might start a phase 2b3 based on the findings from the first cohort. Have you seen that data or is there any other rationale for what seems like a slightly different strategy now with a phase 2 to start next year?
18:20 Great questions, Joseph. So, yeah, I think we are, again, looking to commence enrollment of patients this quarter. We did want to amend the study to include the open label extension, given the availability of our long-term toxicology data. And so we've done that. Our investigators are very excited to start enrolling patients and actually treat them beyond the two-week treatment period. and so we will be getting data from the 1B really in the first half of next year and we'll be able to report out on that data set. And that will be very much informing the phase two study design as well. So we will be getting very important safety, PK information, and biomarker data, and especially looking at NP-PRO-VMP levels, which we're excited to show that data in our preclinical models. We've released that.
19:08 We showed nitrogen reduction in our animal models, looking at OO2 in those preclinical model settings. So we'll be looking to see what data we can generate clinically as well. In terms of our thinking on the Phase II strategy, I think we'll be looking at PBR, again, cardiac function as measured by echo and pro-VMP levels and other biomarkers, as well as six-minute walk tests. So overall, the study design is similar to what we have been planning all along. I think we are saying now that it will likely be a Phase II study that may not be registration-enabling. Based on a lot of conversations we've had, from the regulatory authorities as well as KOL in this space, you know, and then compared to a Phase 2b3 type of approach. However, again, we do think the Phase 2 trial will really position us for success for future registration of studies.
20:01 So it's really more of just understanding, you know, again, through further interactions and assessing what's been going on in the field for our overall strategy. Basically, the study designs and our strategy from what we've been saying is still similar in terms of what we originally laid out.
20:19 Great. That makes sense. Thanks for taking my questions. Thank you. Our next question or comment comes from the line of Patrick Truccio from Barenburg Capital Market. Your line is open.
20:33 Hi. Good afternoon. This is Iris on for Patrick. So, congrats on the progress. I have a few questions. First, on GP001, just to follow up on the LIDAR program, can you tell us what data should we expect to be released at the interim analysis? And then secondly, can you tell us what you would consider to be a comparable benchmark in terms of a particular study for a particular biologic that we should have in mind for the LIDAR trial results? and what should we anticipate in the composite endpoint based on the data generated to date? Thank you.
21:12 Great. Thanks so much.
21:13 So at a time of the interim analysis, that's again when about two-thirds of patients have reached 24 weeks with the primary endpoint. We will be looking at the primary endpoint, which is the composite. We'll be looking at the five subcomponents of the composite. to ensure consistency. And we'll really be looking at the rate of worsened events. So that's really the key endpoint that we'll be looking for at the study. We'll also look, of course, at lung function, and we'll be looking at safety and tolerability as well. Just to be clear, we will not be releasing any of this data since this will be an ongoing study, but we'll be indicating whether we think the data is supportive moving forward into Phase 3 planning and initiation purposes.
22:02 And so that's what the level of disclosure we'll be providing. But really what we'll be looking for is Thank you for your time. For benchmarking purposes, you know, we feel very comfortable looking at the data from the Cajun study. Again, this would be in a different population. But if we're seeing, again, that improvement of the 30 to 50 percent type of improvement in the reduction of worsening events, we'll feel really comfortable that we're in that ballpark. And we will have the benefit, of course, of seeing the Novartis. and a number of others. But again, we'll be looking at consistency across all these events.
23:11 We can't really look at exacerbation solely in the phase two as a primary endpoint just because of the event rates and that we won't have the number of events we need in a shorter-term duration study and a smaller sample size. But again, these are all very correlated in terms of the worsening subcomponent. So it'll give us a very good indication of how we think we will fare in phase three looking at a primary exacerbation endpoint. Okay, a follow-up question on the VARDIS phase three program. So based on your discussions with the FDA and the trial failure, do you think that the FDA would require you to run a similar phase three trial in moderate asthma patient population with the lung function endpoint, or is it possible that the study could be avoided in your pivotal program?
24:05 Yeah, great question. We have had conversations with the FDA where they were very interested in characterizing the efficacy in a broader population beyond moderate to severe eosinophilic asthma patients. We definitely wanted to have that as our patient population for the Phase 2B ELITA study because we think that's where the highest and best scientific rationale lies in terms of the underlying biology for those patients and the potential therapeutic effects for DP2 antagonism as well as any Th2-related mechanism. but we do know that they are interested in that characterization. And Novartis has done quite a bit now to generate data in the moderate asthmatics and the mild to moderate setting as well as looking at the all comers in the luster trial. So our plan is to continue to have a regulatory dialogue and to talk about that plan. We're ready to see the data from, again, our own LIDA study. Of course, we will look at the Lustre 1 and 2 data sets when they become available and take all that back to the regulatory authority to discuss and finalize our phase three plan. I will say that if we are seeing clear benefit in the moderate to severe eosinophilic asthma study and really not a lot of benefit in those other patient populations, we will try to streamline our phase three program.
25:25 We think that's the right thing to do for patients. We also think that's the best use of the resources as well. So those will be some of our intentions. Okay. Another question on GB002.
25:40 So how should we think about the top line data in the Phase 1b study from both a safety and a de-risking perspective? Particularly a safety and pH study is something really difficult to assess. Yeah, so I think primarily this is a safety and tolerability trial in getting experience in pH patients. So that is the primary outcome measures for this study. We will be looking at these biomarkers that we think can be very helpful. and others, and understanding clinical activity around the mechanism, and that includes, again, imaging parameters and looking at right heart function, as well as these pro-BMP levels, which is a measure of right heart strain, and gene expression signatures, which will really be more direct evidence of us on target engagement in our ability to neutralize the mechanism.
26:30 Those will all be very encouraging, and a lot of that will be feeding into our exposure response modeling to finalize a dose selection for Phase II. But, you know, we don't want to guide that we would be seeing proof of concept in the Phase Ib trials. Really, that will be very helpful information for us to do a nice Phase II study. Thanks for taking our question. Thank you. Again, ladies and gentlemen, if you have a question or comment at this time, please press star then 1 on your telephone keypad. I'm sure no additional questions in the queue at this time. I'd like to turn the conference back over to management for any closing remarks.
27:17 Thank you very much. Thank you, everyone, for dialing into the call and for your questions and comments. before to more dialogue over the next few weeks and quarters. Thank you again. Ladies and gentlemen, thank you for participating in today's conference. This concludes the program. You may now disconnect. Everyone, have a wonderful day.
Follow Gossamer Bio, Inc. into a list and get an email when it puts out news.
Analyst, SVB Lyric
Chief Financial Officer, Gossamer Bio
Co-Founder and Chief Executive Officer, Gossamer Bio